Health Care • Medical/Dental Instruments
$66.80 ▼ -2.04
(-2.96%)
MKT CAP: $212.7M • VOL: 32.6K
52W L $54 52W H $77
ROARABLE / RQD
C • 63/100
PIOTROSKI
4 / 9
UTMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $38.5M | $40.9M | $50.2M |
| YoY Revenue Growth % | -5.8% | -18.6% | — |
| Gross Profit | $22.0M | $24.1M | — |
| Gross Margin % | 57.1% | 59.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $11.4M | $13.6M | $16.8M |
| Operating Margin % | 29.6% | 33.2% | 33.4% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | $11.7M | $13.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $14.7M | $14.8M | $22.3M |
| Capital Expenditures (CapEx) | $371.0K | $230.0K | — |
| Free Cash Flow (FCF) | $14.3M | $14.6M | $22.3M |
| FCF Margin % | 37.2% | 35.7% | 44.4% |
| Return on Invested Capital (ROIC %) | 26.9% | 31.2% | — |
| Cash & Short-Term Equivalents | $85.8M | $83.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $119.3M | $117.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR UTMD.